đź‘ĄLondon Life Sciences Week 2025 The busiest week in European life sciences is approaching and Optimum and Catalyst Advisors are here to help you maximise your week. Download our events schedule here to plan ahead, connect smart, and make every moment count! If you have any additional events that you would like to be included, […]
Copenhagen, Denmark, 30 May 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces completion of the single ascending dose stage of its first-in-human trial of VES001 in healthy volunteers. VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as […]
Vesper Bio, backed by Lundbeckfonden BioCapital, initiates a Phase I study to evaluate its lead asset VES001, for the treatment of FTD (GRN mutation), addressing a critical unmet medical need VES001 is a product designed with the needs of the patients and their care givers in mind The Phase I study will assess safety, tolerability […]
